Rosuvastatin to Decrease Residual Immune Activation in HIV Infection
NCT01874743
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class
Conditions
HIV-1 Infection
Interventions
DRUG:
Rosuvastatin 20 mg/day
Sponsor
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Collaborators
[object Object]